However, they still present tumor antigens and induce IL-10-producingCD4+/CD25+ regulatory T cells that inhibit antitumor immunity [130].Nevertheless, using an anti-IL-10 mAb and CpG ODN, it is possible to induce arobust antitumor CTL response and tumor rejection in vivo [111]. Here, IL10 is linked to neoplasm.